Shen Z - Search Results

1

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.

Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ Jr, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ. Adjei AA, et al. Among authors: shen z. Clin Cancer Res. 2016 May 15;22(10):2368-76. doi: 10.1158/1078-0432.CCR-15-1681. Epub 2015 Dec 7. Clin Cancer Res. 2016. PMID: 26644411 Free PMC article. Clinical Trial.

2

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

Weekes CD, Von Hoff DD, Adjei AA, Leffingwell DP, Eckhardt SG, Gore L, Lewis KD, Weiss GJ, Ramanathan RK, Dy GK, Ma WW, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh LT, Dubowy RL, Jeffers M, Rajagopalan P, Clendeninn NJ. Weekes CD, et al. Among authors: shen z. Clin Cancer Res. 2013 Mar 1;19(5):1232-43. doi: 10.1158/1078-0432.CCR-12-3529. Epub 2013 Feb 22. Clin Cancer Res. 2013. PMID: 23434733 Clinical Trial.

3

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.

Shen Z, Rowlings C, Kerr B, Hingorani V, Manhard K, Quart B, Yeh LT, Storgard C. Shen Z, et al. Drug Des Devel Ther. 2015 Jul 2;9:3423-34. doi: 10.2147/DDDT.S85193. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26170627 Free PMC article. Clinical Trial.

4

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.

Shen Z, Gillen M, Miner JN, Bucci G, Wilson DM, Hall JW. Shen Z, et al. Drug Des Devel Ther. 2017 Jul 7;11:2077-2086. doi: 10.2147/DDDT.S140658. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28744099 Free PMC article. Clinical Trial.

5

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.

Baumgartner S, Yeh LT, Shen Z, Kerr B, Manhard K, Quart B. Baumgartner S, et al. Among authors: shen z. J Clin Pharmacol. 2018 Sep;58(9):1164-1170. doi: 10.1002/jcph.1124. Epub 2018 May 7. J Clin Pharmacol. 2018. PMID: 29733441 Free PMC article. Clinical Trial.

6

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.

Hall J, Gillen M, Liu S, Miner JN, Valdez S, Shen Z, Lee C. Hall J, et al. Among authors: shen z. Drug Des Devel Ther. 2018 Jun 20;12:1799-1807. doi: 10.2147/DDDT.S152659. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 29950814 Free PMC article. Clinical Trial.

7

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.

Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B. Miner JN, et al. Among authors: shen z. Arthritis Res Ther. 2016 Oct 3;18(1):214. doi: 10.1186/s13075-016-1107-x. Arthritis Res Ther. 2016. PMID: 27716403 Free PMC article. Clinical Trial.

8

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.

Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M. Kankam M, et al. Among authors: shen z. J Clin Pharmacol. 2018 Sep;58(9):1214-1222. doi: 10.1002/jcph.1119. Epub 2018 May 7. J Clin Pharmacol. 2018. PMID: 29733447 Free PMC article. Clinical Trial.

9

Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.

Yang C, Zhou D, Shen Z, Wilson DM, Renner M, Miner JN, Girardet JL, Lee CA. Yang C, et al. Among authors: shen z. Drug Metab Dispos. 2019 Feb;47(2):104-113. doi: 10.1124/dmd.118.080549. Epub 2018 Nov 15. Drug Metab Dispos. 2019. PMID: 30442650 Clinical Trial.

10

Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.

Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S; RDEA594-111 Study Group. Fleischmann R, et al. Among authors: shen z. Rheumatology (Oxford). 2014 Dec;53(12):2167-74. doi: 10.1093/rheumatology/ket487. Epub 2014 Feb 8. Rheumatology (Oxford). 2014. PMID: 24509406 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10,872 results

Search Page